09:26 AM EDT, 08/20/2025 (MT Newswires) -- Tharimmune ( THAR ) said Wednesday that results from an analysis of its lead drug candidate TH104 showed that it could potentially be used to as a countermeasure for military personnel and chemical incident responders exposed to high-potency opioids, including weaponized fentanyl.

The company said that TH104 helped protect patients from respiratory depression approximately 30 minutes after the dose and lasted for about 24 hours.

Shares of Tharimmune ( THAR ) were up 22% in recent premarket activity.